IP Library Granted Patent US 9,248,112
Granted Patent B2
US 9,248,112 · App. 13/263,189 · Granted Feb 2, 2016

Hemodialysis and peritoneal dialysis solutions comprising one or more creatine compounds

Inventors: Michael Möddel (Dallikon, CH); Theo Wallimann (Bergdietikon, CH)
Assignee: CREARENE LTD.
A61K31/198A61K9/0019A61K9/08A61K47/02A61K47/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,248,112
App. No.
13/263,189
Granted
Feb 2, 2016
Kind
B2
Abstract

The present invention relates to a haemodialysis solution or concentrate thereof comprising creatine compound(s) and the use of creatine compound(s) for preparing a dialysis solution or concentrate thereof. Furthermore, the present invention is directed to a method for preparing creatine-containing dialysis solutions and concentrates. In addition, the present invention is directed to a method for treating patients with dialysis dependent renal failure with creatine compounds and to provide a variety of significant health benefits and improvement of life quality parameters for dialysis patients. This is achieve by supporting and improving the physiological functions of the patients organs and cells via creatine compounds delivery to the patients, and by protecting organs and cells (specifically including blood cells) of these patients from deleterious effects of a variety of endogenous or exogenous cellular stressors that are linked to the disease state or to the clinical treatment modalities. Furthermore in peritoneal dialysis solutions creatine can be used as an osmotic agent preventing side effects caused by high glucose supplementation.

Claims (51)

1. A hemodialysis or peritoneal dialysis solution comprising one or more compounds selected from the group consisting of:

(i) creatine;

(ii) (phospho)creatine;

(iii) (phospho)cyclocreatine;

(iv) homocyclocreatine;

(v) (phospho)creatine monohydrate;

(vi) guanidinoacetic acid;

(vii) 3-guanidinopropionic acid;

(viii) guanidino benzoic acid;

(ix) a combination of glycine, arginine and methionine; and

(x) a physiologically acceptable salt of any of (i) through (ix);

wherein said one or more compounds are present in the hemodialysis or peritoneal dialysis solution at a concentration equivalent to from 0.002 to 45 mM creatine,

wherein the hemodialysis or peritoneal dialysis solution further comprises physiologically acceptable concentrations of sodium and chloride ions, and at least one physiologically acceptable buffering substance, and

wherein the hemodialysis or peritoneal dialysis solution does not contain concentrations of any substances that would make the hemodialysis or peritoneal dialysis solution physiologically unacceptable.

2. The hemodialysis or peritoneal dialysis solution of claim 1 , wherein said concentration equivalent is from 0.05 to 20 mM creatine.

3. The hemodialysis or peritoneal dialysis solution of claim 2 , wherein said concentration equivalent is from 0.05 to 10 mM creatine.

4. The hemodialysis or peritoneal dialysis solution of claim 3 , wherein said concentration equivalent is from 0.1 to 5 mM creatine.

5. The hemodialysis or peritoneal dialysis solution of claim 1 , further comprising physiologically acceptable concentrations of:

(i) potassium, calcium and/or magnesium ions, and

(ii) optionally, a carbohydrate source.

6. The hemodialysis or peritoneal dialysis solution of claim 1 , further comprising a physiologically acceptable additive in a physiologically acceptable concentration, wherein said physiologically acceptable additive is selected from the group consisting of water-soluble vitamins, trace elements, nutrients, and amino acids.

7. An aqueous hemodialysis or peritoneal dialysis solution consisting essentially of, in addition to water,

a) 0.05 to 20 mM of one or more compounds selected from the group consisting of:

(i) creatine;

(ii) (phospho)creatine;

(iii) (phospho)cyclocreatine;

(iv) homocyclocreatine;

(v) (phospho)creatine monohydrate;

(vi) guanidinoacetic acid;

(vii) 3-guanidinopropionic acid;

(viii) guanidino benzoic acid;

(ix) a combination of glycine, arginine and methionine; and

(x) a physiologically acceptable salt of any of (i) through (ix),

b) 130 to 150 mM Na ions,

c) 0 to 10 mM K ions,

d) 0.5 to 3 mM Ca ions

e) 0 to 10 mM Mg ions,

f) 0 to 10 mM Cl ions,

g) 0.2 to 3 g/l glucose,

h) 25 to 40 mM bicarbonate ions, and

i) 1 to 5 mM acetate ions, as physiologically acceptable buffer substances,

wherein the theoretical osmolality of the hemodialysis or peritoneal dialysis solution is 270 to 310 and the pH is in the range of 7.1 to 7.5 , and

wherein the hemodialysis or peritoneal dialysis solution does not contain concentrations of any substances that would make the hemodialysis or peritoneal dialysis solution physiologically unacceptable.

8. The hemodialysis or peritoneal dialysis solution according to claim 1 , wherein the solution does not contain (phospho)creatine.

9. The hemodialysis or peritoneal dialysis solution of claim 8 , wherein said concentration equivalent is from 0.05 to 20 mM creatine.

10. The hemodialysis or peritoneal dialysis solution of claim 8 , wherein said concentration equivalent is from 0.05 to 10 mM creatine.

11. The hemodialysis or peritoneal dialysis solution of claim 8 , wherein said concentration equivalent is from 0.1 to 5 mM creatine.

12. The hemodialysis or peritoneal dialysis solution of claim 8 , further comprising physiologically acceptable concentrations of:

(i) potassium, calcium and/or magnesium ions, and

(ii) optionally, a carbohydrate source.

13. The hemodialysis or peritoneal dialysis solution of claim 8 , further comprising a physiologically acceptable additive in a physiologically acceptable concentration, wherein said physiologically acceptable additive is selected from the group consisting of water-soluble vitamins, trace elements, nutrients, and amino acids.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2020
From: CREARENE LTD.
To: CREARENE AG
Reel/Frame 051666/0684 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2011
From: MODDEL, MICHAEL; WALLIMANN, THEO
To: CREARENE LTD.
Reel/Frame 027369/0665 →
Priority Claims (1)
EP 09005038 · Apr 6, 2009 · regional
Continuity (1)
Related Publication 20120101069A1 · Apr 26, 2012